SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as a major market stabilizer following a blowout earnings report where Azure revenue growth and strong AI demand surpassed expectations, effectively countering recent skepticism around high capital expenditures. Community sentiment remains overwhelmingly bullish, with investors highlighting the company's clear enterprise monetization strategy and cloud dominance as key factors driving institutional call accumulation and renewed confidence in the AI trade.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing extreme volatility as traders clash over the stock's future amid sector-wide rotation and aggressive short-selling activity. The community is sharply divided between bulls betting on massive AI infrastructure demand and infrastructure catalysts, and bears warning of a potential deeper correction following a period of rapid gains.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending due to a blowout earnings report featuring record revenue and significantly raised full-year guidance, which has sparked intense debate among community members about the stock's long-term valuation versus its recent high volatility. While many retail traders are focused on the stock's short-term price action and the impact of forced hedge fund liquidations, others are emphasizing the company's critical role in providing power infrastructure for the rapidly growing AI data center sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant retail interest and debate as shareholders grapple with a disconnect between the company's record-breaking ABS funding deals and its volatile share price. While some investors remain frustrated by the stock's sluggish movement and perceived market manipulation, others are aggressively adding to their positions, highlighting the company's operational growth and recent insider buying as signals of long-term undervaluation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is currently facing heightened volatility and intense scrutiny as investors weigh the company's recent shelf offering filing and ongoing insider selling against the upcoming high-stakes maintenance trial data. While the community remains polarized between those anticipating a major buyout or strategic partnership and those concerned about potential dilution and management's communication, the stock continues to be a focal point for debates regarding clinical pipeline execution and competitive positioning in the weight-loss market.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

The Direxion Daily Semiconductor Bear 3X ETF (SOXS) is trending as retail investors aggressively debate the viability of holding a triple-leveraged inverse product amid extreme volatility in the semiconductor sector. Community discussion is polarized between traders successfully scalping intraday swings and those expressing frustration over the ETF's inherent decay and the broader market's unpredictable reaction to chip sector earnings and macroeconomic developments.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing extreme volatility as traders grapple with tech sector correction fears, mixed AI earnings reports, and geopolitical uncertainty in the Middle East. The community is sharply divided between those calling for a dead cat bounce while remaining cautious of further downside and bulls attempting to buy the dip amid heavy algorithmic trading.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is experiencing heightened volatility following a second-quarter earnings report where record revenue and unit sales were overshadowed by a conservative full-year EBITDA outlook that failed to meet some analyst expectations. The stock remains a major point of contention, as the community debates whether the company's recent growth and profitability represent a genuine turnaround or a sustained attempt to mask underlying financial weakness through accounting maneuvers and reliance on subprime lending.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health shares are experiencing significant volatility as the company manages a challenging transition from a direct-to-consumer cash model to insurance-based revenue, leading to a recent cut in guidance and revenue misses. Despite the negative earnings reaction, the community remains deeply divided, with some investors betting on a long-term turnaround fueled by the Walmart partnership and massive short interest, while others express frustration over leadership execution and persistent stock price weakness.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing extreme volatility as market participants weigh aggressive AI infrastructure demand against growing concerns over potential rate hikes and broader tech sector de-risking. The community remains sharply divided between bulls focused on the company's long-term competitive positioning in the data center market and bears highlighting technical weakness and overextended valuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets PR...

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, July 24, 2026 SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis

Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in...

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Equity

Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.


Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 26, 2026 SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 3, 2026 SAN FRANCISCO, June 3, 2026 /PRNewswire/ --Nektar Therapeutics (NASDAQ: NKTR) today announced...

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PR Newswire SAN FRANCISCO, May 27, 2026 SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar...

$NKTR Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.82 up 49.44% YoY
• Reported revenue of $10.86M up 3.83% YoY
• Nektar Therapeutics expects to initiate the ZENITH-AD Phase 3 program by July 2026 and hold an End-of-Phase 2 meeting with the FDA for alopecia areata in Q2 2026, advancing key pipeline candidates.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NKTRNektar Therapeutics

Fundamentals

Latest NKTR News